Microcap Ledger Neonc Technologies Holdings, Inc. $NTHI
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Calabasas, CA
- Fiscal year end
- December 31
- Shares outstanding
- 25,936,365 [10-Q 2026-08-10]
What the company doesAI summary of filing
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company developing novel drug delivery methods for intracranial malignancies, particularly brain cancers that are difficult to treat due to the blood-brain barrier. The company's lead product, NEO100 (purified perillyl alcohol), is in Phase IIa clinical trials using intranasal delivery for recurrent malignant glioma and meningioma. Its second product, NEO212 (a conjugate of NEO100 and temozolomide), has completed preclinical testing, received FDA investigational new drug approval, and is in a Phase I/II clinical trial for primary and secondary brain tumors. The company generates no revenue and has no approved commercial products or sales infrastructure. [10-K 2026-03-31]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $0.00 | −$23.06M | −$11.76M | $1.97M | [10-Q 2026-08-10] |
| FY ended Dec 2025 | $40.0K | −$62.15M | −$20.36M | $58.7K | [10-K 2026-03-31] |
| FY ended Dec 2024 | $83.0K | −$11.90M | −$4.21M | $64.9K | [10-K 2026-03-31] |
- Quarterly cash burn
- −$5.88M
- Cash runway Estimate
- ~1 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2025-05-09 | 19,026,776 | [10-Q 2025-05-09] |
| 2025-08-18 | 19,159,118 | [10-Q 2025-08-18] |
| 2025-11-14 | 19,474,303 | [10-Q 2025-11-14] |
| 2026-03-30 | 23,806,216 | [10-K 2026-03-31] |
| 2026-05-04 | 25,285,530 | [10-K/A 2026-05-05] |
| 2026-05-15 | 26,013,136 | [10-Q 2026-05-15] |
| 2026-08-10 | 25,936,365 | [10-Q 2026-08-10] |
- Shelf registration
- S-3 filed 2026-06-15; declared effective 2026-06-23 [S-3 2026-06-15]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-15 | Garnett Keithly | sell | 5,000 | $3.36 | [4 2026-09-18] |
| 2026-09-15 | Heshmatpour Amir F | buy | 35,000 | $3.30 | [4 2026-09-15] |
| 2026-09-14 | Heshmatpour Amir F | buy | 15,000 | $3.96 | [4 2026-09-15] |
| 2026-09-14 | Chen Thomas C | buy | 5,242 | $3.81 | [4 2026-09-15] |
| 2026-09-14 | Garnett Keithly | buy | 257 | $3.89 | [4 2026-09-15] |
| 2026-09-11 | Chen Thomas C | buy | 5,556 | $3.60 | [4 2026-09-15] |
| 2026-09-11 | Heshmatpour Amir F | buy | 37,000 | $3.67 | [4 2026-09-14] |
| 2026-08-18 | Chen Thomas C | buy | 12,757 | $5.49 | [4 2026-08-20] |
| 2026-08-18 | Heshmatpour Amir F | buy | 9,000 | $5.54 | [4 2026-08-18] |
| 2026-08-17 | Chen Thomas C | buy | 2,472 | $4.04 | [4 2026-08-18] |
| 2026-08-14 | Chen Thomas C | buy | 33,787 | $3.85 | [4 2026-08-18] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-28 | 8-K | Regulation FD disclosure |
| 2026-09-21 | 8-K | Change to security holder rights; Charter, bylaws or fiscal year change; Regulation FD disclosure |
| 2026-09-17 | 8-K | Regulation FD disclosure |
| 2026-09-10 | 8-K | Material agreement entered; Regulation FD disclosure |
| 2026-09-10 | 424B5 | Prospectus or prospectus supplement |
| 2026-08-21 | 8-K | Director or officer change |
| 2026-08-20 | 8-K | Shareholder vote results |
| 2026-08-13 | 8-K | Regulation FD disclosure |
| 2026-08-12 | 8-K | Regulation FD disclosure |
| 2026-08-10 | 8-K | Results of operations; Regulation FD disclosure |
| 2026-08-10 | 10-Q | Quarterly report |
| 2026-07-15 | 8-K | Regulation FD disclosure |
Alerts for $NTHI
Email me when Neonc Technologies Holdings, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.